144 related articles for article (PubMed ID: 26972577)
1. RGD-modified lipid disks as drug carriers for tumor targeted drug delivery.
Gao J; Xie C; Zhang M; Wei X; Yan Z; Ren Y; Ying M; Lu W
Nanoscale; 2016 Apr; 8(13):7209-16. PubMed ID: 26972577
[TBL] [Abstract][Full Text] [Related]
2. Targeting lipodisks enable selective delivery of anticancer peptides to tumor cells.
Ahlgren S; Reijmar K; Edwards K
Nanomedicine; 2017 Oct; 13(7):2325-2328. PubMed ID: 28712916
[TBL] [Abstract][Full Text] [Related]
3. PEG-stabilized lipid disks as carriers for amphiphilic antimicrobial peptides.
Zetterberg MM; Reijmar K; Pränting M; Engström Å; Andersson DI; Edwards K
J Control Release; 2011 Dec; 156(3):323-8. PubMed ID: 21903146
[TBL] [Abstract][Full Text] [Related]
4. Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity.
Ye R; Zheng Y; Chen Y; Wei X; Shi S; Chen Y; Zhu W; Wang A; Yang L; Xu Y; Peng J
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55902-55912. PubMed ID: 34793125
[TBL] [Abstract][Full Text] [Related]
5. Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo.
Huang C; Jin H; Qian Y; Qi S; Luo H; Luo Q; Zhang Z
ACS Nano; 2013 Jul; 7(7):5791-800. PubMed ID: 23790040
[TBL] [Abstract][Full Text] [Related]
6. Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation.
Tian JL; Ke X; Chen Z; Wang CJ; Zhang Y; Zhong TC
Pharmazie; 2011 May; 66(5):362-7. PubMed ID: 21699070
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
8. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
9. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.
Soman NR; Baldwin SL; Hu G; Marsh JN; Lanza GM; Heuser JE; Arbeit JM; Wickline SA; Schlesinger PH
J Clin Invest; 2009 Sep; 119(9):2830-42. PubMed ID: 19726870
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Immunogenicity and Immunotoxicity of Cyclic RGD Peptide-Modified Nanodrug Delivery Systems.
Wang X; Meng N; Wang S; Lu L; Wang H; Zhan C; Burgess DJ; Lu W
Mol Pharm; 2020 Sep; 17(9):3281-3290. PubMed ID: 32786957
[TBL] [Abstract][Full Text] [Related]
12. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles.
Kim JH; Kim Y; Bae KH; Park TG; Lee JH; Park K
Mol Pharm; 2015 Apr; 12(4):1230-41. PubMed ID: 25686010
[TBL] [Abstract][Full Text] [Related]
14. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery.
Li S; Su Z; Sun M; Xiao Y; Cao F; Huang A; Li H; Ping Q; Zhang C
Int J Pharm; 2012 Oct; 436(1-2):248-57. PubMed ID: 22732672
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
16. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel.
Lollo G; Rivera-Rodriguez GR; Bejaud J; Montier T; Passirani C; Benoit JP; García-Fuentes M; Alonso MJ; Torres D
Eur J Pharm Biopharm; 2014 May; 87(1):47-54. PubMed ID: 24530693
[TBL] [Abstract][Full Text] [Related]
18. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
19. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
20. Linolenic acid-modified PEG-PCL micelles for curcumin delivery.
Song Z; Zhu W; Liu N; Yang F; Feng R
Int J Pharm; 2014 Aug; 471(1-2):312-21. PubMed ID: 24939613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
